Foghorn therapeutics provides 2023 outlook and full year 2022 corporate update

- phase 1 dose escalation study of fhd-286, a brg1/brm inhibitor, in metastatic uveal melanoma continues to progress with initial safety and efficacy data expected in the first half of 2023
FHTX Ratings Summary
FHTX Quant Ranking